DKFZ 4 records found  Search took 0.01 seconds. 
pmc [DKFZ-2022-03108] Journal Article
; ; ; et al
BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer.
Evasion of apoptosis is a hallmark of cancer, which is frequently mediated by upregulation of the antiapoptotic BCL-2 family proteins. In colorectal cancer (CRC), previous work has highlighted differential antiapoptotic protein dependencies determined by the stage of the disease. [...]
DBCoverage [DKFZ-2022-03107] Journal Article
; ; ; et al
Active elimination of intestinal cells drives oncogenic growth in organoids.
Competitive cell interactions play a crucial role in quality control during development and homeostasis. Here, we show that cancer cells use such interactions to actively eliminate wild-type intestine cells in enteroid monolayers and organoids. [...]
[DKFZ-2022-00861] Journal Article
; ; ; et al
Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.
Gut 71(12), 2502-2517 () [10.1136/gutjnl-2021-326183]  GO
Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy.To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of in vitro and stroma-rich in vivo models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in human tumours.By performing our analyses specifically within the stroma-rich/high-fibroblast (HiFi) subtype of CC, we identify and validate the clinical value of a HiFi-specific prognostic signature (HPS), which stratifies tumours based on STAT1-related signalling (High-HPS v Low-HPS=HR 0.093, CI 0.019 to 0.466). [...]
[DKFZ-2021-00091] Journal Article (Review Article)
; ; ; et al
Advances in colon cancer research: in vitro and animal models.
Modelling human colon cancer has long been the ambition of researchers and oncologists with the aim to better replicate disease progression and treatment response. Advances in our understanding of genetics, stem cell biology, tumour microenvironment and immunology have prepared the groundwork for recent major advances. [...]

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.